Inhibitex to Present at the Jefferies 2011 Global Healthcare Conference
June 01 2011 - 9:21AM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell
Plumb, president and chief executive officer, will present an
overview of the Company and an update of its pipeline of
differentiated anti-infective compounds at the Jefferies 2011
Global Healthcare Conference on June 6, 2011 at 8:00 AM (EDT). The
conference is being held at the Grand Hyatt Hotel in New York
City.
About Inhibitex
Inhibitex, Inc., is a biopharmaceutical company focused on
developing products to prevent and treat serious infectious
diseases. The Company’s clinical-stage pipeline includes FV-100, a
nucleoside inhibitor in Phase II for the treatment of shingles, and
INX-189, a nucleotide polymerase inhibitor in Phase 1b for the
treatment of chronic hepatitis C infections. The Company also has
additional HCV nucleotide polymerase inhibitors in preclinical
development and has licensed the use of its proprietary MSCRAMM®
protein platform to Pfizer for the development of a staphylococcal
vaccine, which is currently being evaluated in a Phase 1 clinical
trial. For additional information about the Company, please visit
www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024